-- プーナワラ・フィンコープ（NSE:POONAWALLA、BOM:524000）は、インド証券取引所への金曜日の提出書類によると、私募方式による非転換社債の発行を通じて15億5000万インドルピーを調達した。 同社は、額面10万ルピーの無担保、償還可能、格付け済み、上場、劣後非転換社債1万5500口を割当た。基本発行額は15億ルピーで、5000万ルピーの超過応募分を留保するグリーンシューオプションが付いている。 この社債のクーポン利率は年率8.43%で、2036年4月24日に満期を迎える。ボンベイ証券取引所（BSE）の債券市場セグメントへの上場が予定されている。 同社の株価は直近の取引で約2％下落した。
Related Articles
Asia
National Australia Bank Shares Down After Resolution of Union Court Proceedings
National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."
$ASX:NAB
Asia
Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant
Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.
$ASX:CUV
Asia
XRF Scientific Completes Acquisition of Combustion Gas Analysis Business
XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.
$ASX:XRF